Market Intelligence · India CDMO 2026

India's Sterile CDMO
Moment Has Arrived

India is the world's pharmacy — supplying 20% of global generic medicines. The next frontier is sterile injectables CDMO, where infrastructure, regulation, and cost converge to make India the preferred outsourcing destination.

$8B
India Pharma CDMO Market 2030
16%
CAGR 2024–2030 (sterile segment)
20%
Global generics supplied by India
3,000+
WHO-GMP certified plants in India
The Market Opportunity

Why India for
Sterile CDMO?

India's pharmaceutical sector has transformed from a domestic generics supplier to a globally regulated manufacturing powerhouse. With over 3,000 WHO-GMP certified plants and 800+ USFDA-approved facilities, India offers the regulatory pedigree that global innovators and generics companies demand from CDMO partners.

The sterile injectables segment is growing at 16% CAGR — outpacing oral solid dosage — driven by biosimilar launches, oncology portfolios, hospitalisation rates, and the global shift toward prefilled syringe delivery systems. India sits at the convergence point of this growth.

For domestic pharmaceutical companies, increasing regulatory scrutiny and capital-intensive cleanroom infrastructure requirements make outsourcing to a GMP-certified CDMO the strategically superior option versus in-house investment.

Key CDMO Demand Drivers for Sterile Injectables in India
Escalating demand for biologics and biosimilar injectables requiring aseptic fill-finish
Government PLI Scheme incentivising domestic pharmaceutical manufacturing investment
Rising hospital-acquired infection awareness driving sterile single-dose formulation demand
China+1 strategy by global pharma accelerating Indian CDMO partnerships
Ophthalmology, cardiology, and oncology portfolios increasingly requiring PFS & vial formats
Growth Drivers

What's Powering
The Surge

Regulatory Parity

Indian GMP standards increasingly aligned with EU Annex 1 and USFDA 21 CFR Part 211, reducing re-audit burden for global partners.

Cost Competitiveness

Indian sterile manufacturing costs 40–60% lower than comparable European and US CDMO partners — without compromising quality standards.

Speed to Market

Established supply chains for API, excipients, primary packaging, and logistics enable faster tech transfer and batch turnaround than greenfield alternatives.

Global CDMO Comparison

India vs Global CDMO Locations

ParameterIndia ★ChinaEuropeUSA
GMP Certification Quality✓ WHO / USFDA✓ China GMP✓ EU Annex 1✓ cGMP
Sterile Manufacturing CostVery LowLowHighVery High
Regulatory Track Record✓ StrongImproving✓ Excellent✓ Excellent
Supply Chain Risk (post-COVID)✓ Low⚠ Elevated✓ Moderate✓ Low
Tech Transfer Agility✓ Fast✓ FastModerateModerate
API Self-Sufficiency✓ High✓ Very HighModerateLow
Geopolitical Stability✓ Stable⚠ Risk Elevated✓ Stable✓ Stable
The Addams Edge

Your India CDMO Partner
— Right in Rajasthan

GMP Certified Sterile Facility
Our Sandri unit operates to current GMP standards with ISO 5 aseptic core — fully audit-ready for domestic and semi-regulated market partners.
120 Units/Minute Capacity
Dual-line sterile manufacturing delivers up to 172,800 units/day — scalable to your volume requirements with minimal lead time.
3 Formats, 10 Molecules
PFS, Vials, and Eye Drops across cardiology, oncology support, ophthalmology, anaesthesia, and nutrition — from one manufacturing partner.
Rajasthan — Strategic Location
Central India positioning with excellent road and rail connectivity to Delhi, Mumbai, and major pharmaceutical distribution hubs nationwide.
Partner with India's Growing Sterile CDMO
Join the India pharmaceutical outsourcing wave. Contact Addams to discuss your sterile manufacturing requirements.
Start DiscussionGet Quote